KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and Manufacturing
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform™, that allows for optimized, safe, and cost-efficient monoclonal antibody (mAb) development and manufacturing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912612750/en/
(Photo: Business Wire)
SUREmAb is a vertically integrated global offering designed to minimize development timelines for global biopharmaceutical manufacturers, delivering research cell bank (RCB) development in as little as 9 weeks and the ability for customers to move from DNA to GMP drug substance in as few as 11 months. In addition, SUREmAb is engineered to achieve titers of up to 10 g/L with a lower-cost workflow to optimize operational efficiency and maximize ROI.
"SUREmAb represents not just the culmination of decades of biologics production expertise but our vision for the future of mAb development,” said KBI Chief Scientific Officer, Sigma Mostafa. “In an era where time, efficiency, and innovation converge, we're proud to introduce a platform that can not only accelerate the development journey but is high quality and cost-effective, from the start. At KBI, we believe in anticipating market shifts and pioneering solutions that address tomorrow's challenges today, and SUREmAb is a testament to that commitment."
The operational consolidation of KBI Biopharma and Selexis, announced during BIO International 2023, played an important role in the operations that power the SUREmAb technology, enabling KBI to streamline processes and offer greater efficiencies in monoclonal antibody development and manufacturing. This offering strengthens KBI’s industry expertise and position within global markets by building on more than 15 years of mAb development leadership, with over 150 unique therapeutic mAb projects and 7 commercialized mAbs leveraging the SUREtechnology Platform.
“We recognize the need to be a strong partner for customers with novel therapies so that they have the best chance of reaching as many patients as possible,” said KBI CEO, J.D. Mowery. “The simplified access to SUREmAb and ongoing manufacturing with KBI shows our commitment to supporting the industry by improving a key barrier to development.”
SUREmAb complies with global regulatory standards, ensuring straightforward experiences when targeting markets regulated by the US FDA, EMA and PMDA.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 400 drug candidates in preclinical and clinical development and the manufacture of 10 commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912612750/en/
Contact information
KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Blair Ciecko
CG Life
bciecko@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
XPENG Shipped 750 Vehicles to Israel, Coming Closer to G9 and P7's Launch in October27.9.2023 17:02:00 EEST | Press release
XPENG (NYSE: XPEV and HKEX: 9868), a leading smart electric vehicle company, today announced that it has shipped 750 vehicles for the Israeli market, marking this the largest single batch of export this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927239985/en/ Hey XPENG, navigate to Israel! (Photo: Business Wire) The batch left the Guangzhou Port after the conclusion of a ceremony that included local customs officials and port representatives. “We're very grateful for the support of our partners and the local customs officials as we take a significant step toward launching in Israel," said Eric Xu, VP of International Markets, XPENG. "With the help of our local partner, Freesbe, the launch of our smart EVs is just around the corner—and we can't wait." The two models expected to be available in Israel, XPENG P7 and XPENG G9, have also been adapted to meet the preferences of local drivers. Together with Freesbe, wi
SoftServe Debuts Sage, the AI Pathfinder, at Money20/2027.9.2023 16:03:00 EEST | Press release
SoftServe, a premier IT consulting and digital services provider, will debut Sage, the AI Pathfinder, a financial intelligence consultant powered by Generative AI using NVIDIA Avatar Cloud Engine (ACE), at Money20/20 USA. Attendees can interact with the immersive experience offering financial decisioning and education at booth #13117 starting Oct. 22. Sage, the AI Pathfinder, is enhanced with a customized ChatGPT module combined with visual avatars and dynamic content. It features real-time information processing for interactive decision-making to offer personalized financial recommendations. Financial wellness is a struggle for 58% of Americans living paycheck to paycheck. Only 51% have more emergency savings than credit card debt. “A lack of financial literacy is a big part of this problematic equation,” said Filippa Noghani, AVP of Marketing at SoftServe and NYC Fintech Women Board Member. “Generative AI technologies create promising educational opportunities, especially for millenn
PPG’s COLORFUL COMMUNITIES program marks 500th project with makeover at Carnegie Science Center in Pittsburgh27.9.2023 16:00:00 EEST | Press release
PPG (NYSE:PPG) today announced the completion of its 500th COLORFUL COMMUNITIES® project – a colorful and transformational makeover at Carnegie Science Center in Pittsburgh. More than 80 volunteers marked the milestone by creating science-themed murals and applying fresh paint and color in learning spaces around the center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927335327/en/ PPG volunteers completed the 500th COLORFUL COMMUNITIES® project at the Carnegie Science Center in Pittsburgh, kicking off a month-long, worldwide celebration. (Photo: Business Wire) Completion of the 500th Colorful Communities project kicks off a month-long, worldwide celebration of the volunteers, community partners and individuals who have helped to bring color and brightness to PPG communities. From China to the Netherlands, additional projects are planned across the world to mark the milestone. “When we launched the Colorful Communities
Syntropy Announces Collaboration with Evidium to Advance Data-Centric Healthcare27.9.2023 16:00:00 EEST | Press release
Today, Syntropy, a partnership between Merck and Palantir Technologies Inc., announced a collaboration with Evidium, a developer of a healthcare platform that enables AI use in a responsible, reliable, and referenceable manner. The organizations will make end-to-end medical knowledge more computational and improve data quality for clinical research and practice. The coalition will be facilitated through Syntropy’s secure data collaboration platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927301328/en/ Evidium’s Referenced AI platform will play a key role in transforming narrative-form information into AI-ready knowledge at the elemental level. This will allow clinical data to be disseminated and utilized with unprecedented scale and precision. Syntropy’s secure, collaborative ecosystem will enable researchers to review high-quality data, share insights, and apply their findings to clinical trials, helping to gener
Afiniti Appoints Hassan Afzal as Its Chief Executive Officer27.9.2023 16:00:00 EEST | Press release
Afiniti, the leading provider of AI-enabled enterprise behavioral pairing solutions for customer interactions, has announced the appointment of Hassan Afzal as Afiniti’s Chief Executive Officer and Board Director. Mr. Afzal, an experienced business leader, will succeed Larry Babbio, who assumed the position of Chief Executive Officer of Afiniti in 2021. His appointment is the culmination of a CEO succession plan and subsequent search process undertaken by the Board. The Board of Directors is grateful to Mr. Babbio for his unwavering commitment to Afiniti and is pleased that the company will continue to benefit from his experience as he will remain with Afiniti as a Board Director. Mr. Afzal joined Afiniti in 2007 as one of its first employees and has served as its Chief Technology Officer, making him a key architect of Afiniti’s unique and patented technology. He has been a core enabler of Afiniti’s growth to its current scale of about 1,500 employees across 20 countries. Mr. Afzal hol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom